174 related articles for article (PubMed ID: 27538511)
21. Arginine deiminase, a potential anti-tumor drug.
Ni Y; Schwaneberg U; Sun ZH
Cancer Lett; 2008 Mar; 261(1):1-11. PubMed ID: 18179862
[TBL] [Abstract][Full Text] [Related]
22. Anti-tumor activity of arginine deiminase from Mycoplasma argini and its growth-inhibitory mechanism.
Takaku H; Matsumoto M; Misawa S; Miyazaki K
Jpn J Cancer Res; 1995 Sep; 86(9):840-6. PubMed ID: 7591961
[TBL] [Abstract][Full Text] [Related]
23. Microbial arginine deiminase: A multifaceted green catalyst in biomedical sciences.
Kawatra A; Dhankhar R; Gulati P
Int J Biol Macromol; 2022 Jan; 196():151-162. PubMed ID: 34920062
[TBL] [Abstract][Full Text] [Related]
24. Targeting argininosuccinate synthetase negative melanomas using combination of arginine degrading enzyme and cisplatin.
Savaraj N; Wu C; Li YY; Wangpaichitr M; You M; Bomalaski J; He W; Kuo MT; Feun LG
Oncotarget; 2015 Mar; 6(8):6295-309. PubMed ID: 25749046
[TBL] [Abstract][Full Text] [Related]
25. Recombinant human arginase inhibits proliferation of human hepatocellular carcinoma by inducing cell cycle arrest.
Lam TL; Wong GK; Chong HC; Cheng PN; Choi SC; Chow TL; Kwok SY; Poon RT; Wheatley DN; Lo WH; Leung YC
Cancer Lett; 2009 May; 277(1):91-100. PubMed ID: 19138817
[TBL] [Abstract][Full Text] [Related]
26. Improved method for expression and isolation of the Mycoplasma hominis arginine deiminase from the recombinant strain of Escherichia coli.
Fayura LR; Boretsky YR; Pynyaha YV; Wheatley DN; Sibirny AA
J Biotechnol; 2013 Sep; 167(4):420-6. PubMed ID: 23928331
[TBL] [Abstract][Full Text] [Related]
27. Protein engineering of the antitumor enzyme PpADI for improved thermal resistance.
Zhu L; Cheng F; Piatkowski V; Schwaneberg U
Chembiochem; 2014 Jan; 15(2):276-83. PubMed ID: 24375953
[TBL] [Abstract][Full Text] [Related]
28. Enhancement of anti-tumor activity in melanoma using arginine deiminase fused with 30Kc19α protein.
Lee H; Park G; Kim S; Son B; Joo J; Park HH; Park TH
Appl Microbiol Biotechnol; 2022 Nov; 106(22):7531-7545. PubMed ID: 36227339
[TBL] [Abstract][Full Text] [Related]
29. Regression of hepatocellular cancer in a patient treated with arginine deiminase.
Curley SA; Bomalaski JS; Ensor CM; Holtsberg FW; Clark MA
Hepatogastroenterology; 2003; 50(53):1214-6. PubMed ID: 14571701
[TBL] [Abstract][Full Text] [Related]
30. Arginine deiminase expressed in vivo, driven by human telomerase reverse transcriptase promoter, displays high hepatoma targeting and oncolytic efficiency.
Jiang H; Guo S; Xiao D; Bian X; Wang J; Wang Y; Zhou H; Cai J; Zheng Z
Oncotarget; 2017 Jun; 8(23):37694-37704. PubMed ID: 28455966
[TBL] [Abstract][Full Text] [Related]
31. A potential antitumor drug (arginine deiminase) reengineered for efficient operation under physiological conditions.
Zhu L; Verma R; Roccatano D; Ni Y; Sun ZH; Schwaneberg U
Chembiochem; 2010 Nov; 11(16):2294-301. PubMed ID: 20954230
[TBL] [Abstract][Full Text] [Related]
32. High sensitivity of human melanoma cell lines to the growth inhibitory activity of mycoplasmal arginine deiminase in vitro.
Sugimura K; Ohno T; Kusuyama T; Azuma I
Melanoma Res; 1992 Sep; 2(3):191-6. PubMed ID: 1450673
[TBL] [Abstract][Full Text] [Related]
33. The role of arginine and the modified arginine deiminase enzyme ADI-PEG 20 in cancer therapy with special emphasis on Phase I/II clinical trials.
Synakiewicz A; Stachowicz-Stencel T; Adamkiewicz-Drozynska E
Expert Opin Investig Drugs; 2014 Nov; 23(11):1517-29. PubMed ID: 24965808
[TBL] [Abstract][Full Text] [Related]
34. Selective Intracellular Delivery of Recombinant Arginine Deiminase (ADI) Using pH-Sensitive Cell Penetrating Peptides To Overcome ADI Resistance in Hypoxic Breast Cancer Cells.
Yeh TH; Chen YR; Chen SY; Shen WC; Ann DK; Zaro JL; Shen LJ
Mol Pharm; 2016 Jan; 13(1):262-71. PubMed ID: 26642391
[TBL] [Abstract][Full Text] [Related]
35. Purification of a dimeric arginine deiminase from Enterococcus faecium GR7 and study of its anti-cancerous activity.
Kaur B; Kaur R
Protein Expr Purif; 2016 Sep; 125():53-60. PubMed ID: 26363115
[TBL] [Abstract][Full Text] [Related]
36. Arginine-Depleting Enzymes - An Increasingly Recognized Treatment Strategy for Therapy-Refractory Malignancies.
Riess C; Shokraie F; Classen CF; Kreikemeyer B; Fiedler T; Junghanss C; Maletzki C
Cell Physiol Biochem; 2018; 51(2):854-870. PubMed ID: 30466103
[TBL] [Abstract][Full Text] [Related]
37. Arginine deiminase of Mycoplasma hominis: cytoplasmic and membrane-associated forms.
Lin JS
J Gen Microbiol; 1986 Jun; 132(6):1467-74. PubMed ID: 3806049
[TBL] [Abstract][Full Text] [Related]
38. [Mechanism of arginine deiminase activity by site-directed mutagenesis].
Li L; Ni Y; Sun Z
Sheng Wu Gong Cheng Xue Bao; 2012 Apr; 28(4):508-19. PubMed ID: 22803400
[TBL] [Abstract][Full Text] [Related]
39. Arginine depriving enzymes: applications as emerging therapeutics in cancer treatment.
Kumari N; Bansal S
Cancer Chemother Pharmacol; 2021 Oct; 88(4):565-594. PubMed ID: 34309734
[TBL] [Abstract][Full Text] [Related]
40. Arginine deiminase enhances MCF-7 cell radiosensitivity by inducing changes in the expression of cell cycle-related proteins.
Park H; Lee JB; Shim YJ; Shin YJ; Jeong SY; Oh J; Park GH; Lee KH; Min BH
Mol Cells; 2008 Apr; 25(2):305-11. PubMed ID: 18414006
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
